The Umbelliprenin-CTAB cellulose nanocrystal delivery system prevents hyperglycemia in diabetic rats by activating the insulin receptor IR/PDK1 pathway.

AmirBagher Ilkhani, Maryam Tehranipour, Jina Khayatzade, Akram Eidi

Abstract read

In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

AmirBagher IlkhaniDepartment of Biology, SR.C., Islamic Azad University, Tehran, Iran.

Maryam TehranipourDepartment of Biology, Ma.C., Islamic Azad University, Mashhad, Iran. Maryam_tehranipour@iau.ac.ir.

Jina KhayatzadeDepartment of Biology, Ma.C., Islamic Azad University, Mashhad, Iran.

Akram EidiDepartment of Biology, SR.C., Islamic Azad University, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Today, with the prevalence of metabolic diseases such as diabetes, which can be caused by insulin resistance, the need for targeted drug delivery seems essential. Using Nano crystals that contain antioxidant materials such as Umbelliprenin and are surface modified may be a solution to this problem. This study aims to investigate the IR/PDK1 pathway in the presence of cellulose nano-crystal surface-modified with cetyltrimethylammonium bromide containing Umbelliprenin (UCC-NCs delivery system). The UCC-NCs delivery system was synthesized and characterized by FTIR and zeta-potential methods. Forty-two Wistar male rats (aged 12 weeks, 250-300 g) were divided into seven groups of six. After induction of diabetes with a single dose of intraperitoneal injection of STZ (60 mg.kg

Indexed as

CelluloseCetrimoniumDiabetes Mellitus, ExperimentalDrug Delivery SystemsHyperglycemiaNanoparticlesUmbelliferonesAnimalsBlood GlucoseMalePyruvate Dehydrogenase Acetyl-Transferring KinaseRatsRats, WistarSignal TransductionBlood GlucoseCelluloseCetrimoniumPdk1 protein, ratPyruvate Dehydrogenase Acetyl-Transferring KinaseUmbelliferonesAnti-diabeticCellulose nano crystals surface-modified with cetyltrimethylammonium bromide containing Umbelliprenin (UCC-NCs delivery system)IR/PDK1 pathwayPancreatic protective activityUmbelliprenin

Identifiers

PMID41093961

DOI10.1038/s41598-025-20069-8

PMCPMC12528772

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.